Ocular diagnosis of Alzheimer's disease
First Claim
1. A method of diagnosing Alzheimer'"'"'s Disease in a mammal, the method comprising contacting an ocular tissue with a detectably-labeled compound that binds to an amyloid protein, wherein the compound is a fluorescent dye, wherein an increase in binding of said compound to said ocular tissue compared to a normal control level of binding indicates that said mammal is suffering from or is at risk of developing Alzheimer'"'"'s Disease.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention features a method of diagnosing or providing a prognosis regarding the state of Alzheimer'"'"'s Disease in a mammal by contacting an ocular tissue with a detectably-labeled compound, which binds to an amyloid protein. An increase in binding of the compound to the ocular tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer'"'"'s Disease.
36 Citations
49 Claims
- 1. A method of diagnosing Alzheimer'"'"'s Disease in a mammal, the method comprising contacting an ocular tissue with a detectably-labeled compound that binds to an amyloid protein, wherein the compound is a fluorescent dye, wherein an increase in binding of said compound to said ocular tissue compared to a normal control level of binding indicates that said mammal is suffering from or is at risk of developing Alzheimer'"'"'s Disease.
- 12. A method of diagnosing Alzheimer'"'"'s Disease in a mammal, the method comprising contacting an ocular tissue with a detectably-labeled compound that binds to an amyloid protein, wherein the compound is detectably-labeled with a positron emitting radionuclide and wherein an increase in binding of said compound to said ocular tissue compared to a normal control level of binding indicates that said mammal is suffering from or is at risk of developing Alzheimer'"'"'s Disease.
- 23. A method of diagnosing Alzheimer'"'"'s Disease in a mammal, the method comprising contacting an ocular tissue with a detectably-labeled compound that binds to an amyloid protein, wherein the compound is detectably-labeled with a radioactive label and wherein an increase in binding of said compound to said ocular tissue compared to a normal control level of binding indicates that said mammal is suffering from or is at risk of developing Alzheimer'"'"'s Disease.
- 34. A method of diagnosing Alzheimer'"'"'s Disease in a mammal, the method comprising using magnetic resonance imaging to determine an amount of an amyloid protein present in an ocular tissue, wherein an increase in the amount of said amyloid protein of said amyloid protein present in the ocular tissue compared to the amount of amyloid protein present in a normal ocular tissue indicates that said mammal is suffering from or is at risk of developing Alzheimer'"'"'s Disease.
- 41. A method of diagnosing Alzheimer'"'"'s Disease in a mammal, the method comprising using magnetic resonance imaging to determine an anatomical location of an amyloid protein present in an ocular tissue, wherein a difference in the anatomical location of said amyloid protein present in the ocular tissue compared to the anatomical location present in a normal ocular tissue indicates that said mammal is suffering from or is at risk of developing Alzheimer'"'"'s Disease.
-
49. A method for prognosis of Alzheimer'"'"'s Disease, the method comprising:
-
a) contacting ocular tissue of a mammal with a compound which binds to an amyloid polypeptide. b) quantitating the level of association of said compound with said ocular tissue; and
c) comparing the level of association with a normal control level of association, wherein increasing levels of association over time indicates an adverse prognosis, wherein the quantitating is accomplished by positron emission tomography, radioimaging, radioimmunoassay, or magnetic resonance imaging.
-
Specification